More than 200 deaths with suspected weight-loss jabs links reported to regulator
Regulators have also received reports of more than 158,000 adverse reactions linked to the popular medications
Health officials have received reports of more than 200 deaths suspected of being linked to weight-loss jabs, figures suggest.
Listen to this article
Regulators have also received reports of more than 158,000 adverse reactions linked to the popular medications.
If people suspect that an adverse reaction is linked to a medicine, they can report it to the Medicine and Healthcare Products Regulatory Agency’s (MHRA) Yellow Card Scheme.
Data from the scheme indicate that 106,189 adverse reactions – including gastrointestinal problems – and 120 deaths have been reported to the scheme regarding tirzepatide, which is sold under the brand name Mounjaro.
Some 48,089 reactions and 59 deaths have been reported as being suspected of being linked to semaglutide, which is the active ingredient for the weight-loss drug Wegovy.
Read more: Avoid these three things to get 13 more years without dementia, experts say
Semaglutide is also the active ingredient for diabetes treatments Ozempic and Rybelsus.
Meanwhile, 4,491 adverse reactions and 37 deaths have been reported as being suspected to be linked to liraglutide, which is sold under the brand name Saxenda.
This drug is also used to treat diabetes under different brand names.
The regulator said that adverse reactions and deaths reported to its Yellow Card Scheme did not necessarily mean that the death or the reaction was caused by the medicine, only that the reporter had a suspicion it may have been.
An MHRA spokesperson said: “It is important to place these reports in the context of the millions of GLP-1 prescriptions issued in the UK.
“Reporting volumes can be influenced by increased use, greater awareness of a potential adverse reaction and other factors.
“As with all medicines, the safety of GLP-1s are kept under continual review including emerging evidence from spontaneous data and scientific publications.
“Any potential updates regarding the safety for these medicines would be promptly communicated to patients and healthcare professionals, and appropriate steps taken to mitigate any identified risk.
“On the basis of the current evidence, the benefits of GLP-1 receptor agonists outweigh the potential risks when used in line with their authorised uses.”
Health Secretary Yvette Cooper told LBC: “We have a whole system of health safety regulations in place where experts will do monitoring of any adverse impacts, of any safety reports, any concerns that are raised.
“And the good thing about the fact that we have a National Health Service means that all of those reports can be collected together – all of them can be monitored.
“And we ensure that those experts, the expert regulators, are monitoring that at all times and making sure if there are any wider concerns, if there are any issues that need to be raised, then they are brought to the health secretary, to health ministers, as well as to the public, to make sure that safety is always paramount.”